Our Science | Taiga Biotechnologies, Inc.

Taiga Biotechnologies, Inc.'s technology is centered around boosting the immune system to better fight disease.

BRAND NEW CLASS OF CELL THERAPY

TBX-4000 is a proprietary protein of Taiga Biotechnologies, Inc. and is a fusion of the Trans-Activator Transcription (TAT) protein and the MYC protein. TBX-4000 is crucial to the development and function of TBX-3400 and TBX-2400.

MYC is the key regulator of cellular function.
TAT is the “payload” carrier that enables TBX-4000 to penetrate the cell membrane.
Once inside the cell, MYC is shuttled to the nucleus where it exerts its function.

Reviewed By US FDA, EMA, Japan MHLW, Israel MoH

TBX-4000 master file with the FDA

MULTIPLE APPLICATIONS

HOW IT WORKS COMPARED TO OTHER THERAPIES

T-Cell Activation

Activation of the T-cell

T-cells identify tumor cells and become activated through a series of interactions.

When activated, the T-cell:

Targets and kills the tumor cell.
Proliferates, creating more T-cells that are able to identify and kill the tumor cell.

Tumor Evading Attack

Evade attack from the T-cell

Tumors evade T-cell attack by disguising themselves as “self” cells through the use of immune checkpoint receptors on its cell surface.

Two Mechanisms:

Certain Immune Checkpoints compete for the Signal 2 binding site on the Tumor Cell, inhibiting Signal 2 from occurring.
Other Immune Checkpoints interactions occur which lead to further inactivation of the T-Cell.

Checkpoint Inhibitors

Blocking the Immune Checkpoint Receptor

Competitors have developed therapies that use one or a combination of checkpoint inhibitors to block the interaction.

Issues:

TBX-3400

Down-regulate the Checkpoint Receptors

We have data that shows TBX-3400 cells show decreased expression of immune checkpoint receptors.

Without these checkpoint receptors expressed, the T-cell is able to become activated, recognize the tumor and kill it.

Advantages: